戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ex and subsequently estimate tissue-specific pharmacokinetic parameters.
2 n between UGT1A1*28 genotype and toxicity or pharmacokinetic parameters.
3 t of therapeutic glycoproteins with improved pharmacokinetic parameters.
4 pockets so as to improve affinity and adjust pharmacokinetic parameters.
5 purposes and for the determination of common pharmacokinetic parameters.
6 in, with negligible interdose variability in pharmacokinetic parameters.
7  for chronic HBV disease using HBIg dosed by pharmacokinetic parameters.
8 ed second-generation FXRa/sEHi with improved pharmacokinetic parameters.
9 d to reduce oxidative metabolism and improve pharmacokinetic parameters.
10 portant physiochemical, pharmacodynamic, and pharmacokinetic parameters.
11 he Tofts model to segment tumors and analyze pharmacokinetic parameters.
12 lar potency, drug target residence time, and pharmacokinetic parameters.
13 le-cell antitubercular activity, and in vivo pharmacokinetic parameters.
14 on interaction with human GlgB and in silico pharmacokinetic parameters.
15 ts by two SP (deviations < 15%), and correct pharmacokinetic parameters.
16 n administration did not influence melphalan pharmacokinetic parameters.
17 yl-JNJ-31020028 is sufficient for estimating pharmacokinetic parameters.
18 d consistently high oral bioavailability and pharmacokinetic parameters across preclinical animal spe
19                                           No pharmacokinetic parameters after oral administration wer
20 ere no significant differences in vorinostat pharmacokinetic parameters among the normal or hepatic d
21 ed for only 18% of intersubject variation in pharmacokinetic parameters and 32% to 64% of intersubjec
22 ated sustained clinical responses, favorable pharmacokinetic parameters and a 6-month progression-fre
23 2 hrs after this dose, in order to determine pharmacokinetic parameters and calculate the optimum mai
24                             Breath and blood pharmacokinetic parameters and cannabinoid profiles dete
25  can capitalize on the improved and flexible pharmacokinetic parameters and excellent (18)F-fluorinat
26  and urine samples were assayed to determine pharmacokinetic parameters and excretion.
27      Blood samples were assayed to determine pharmacokinetic parameters and IGF-1R occupancy on neutr
28                       It has more consistent pharmacokinetic parameters and improved bioavailability
29                                   Population pharmacokinetic parameters and interindividual variabili
30     The compound was shown to have excellent pharmacokinetic parameters and lowered rat plasma LH lev
31 e" addressing the effect of NGR-hTNF on drug pharmacokinetic parameters and on vessel permeability, a
32                     Assessment of associated pharmacokinetic parameters and pharmacokinetic/pharmacod
33 an in vitro inhibitory assay to evaluate its pharmacokinetic parameters and potency in a CDI mouse mo
34 eighing 3 kg to less than 20 kg by assessing pharmacokinetic parameters and safety data in children t
35  clinical study is designed to determine the pharmacokinetic parameters and the incidence of adverse
36                                     Baclofen pharmacokinetic parameters and their correlations with b
37 the largest relational database of dendrimer pharmacokinetic parameters and their structural/physicoc
38                                 However, the pharmacokinetic parameters and urinary drug clearance in
39  Radiation dosimetry calculations determined pharmacokinetics parameters and absorbed alpha-emission
40 hly valuable resource for the text mining of pharmacokinetics parameters and drug interactions.
41 ot only led to improved metabolic stability, pharmacokinetic parameters, and in vitro activity agains
42 u, including improved in vitro potency, good pharmacokinetic parameters, and in vivo efficacy higher
43                The maximum tolerated dosage, pharmacokinetic parameters, and pharmacokinetic/pharmaco
44        The estimates of radiation dosimetry, pharmacokinetic parameters, and safety profile in this s
45 ed favorable tissue distribution, controlled pharmacokinetic parameters, and significant triglyceride
46                                    Linezolid pharmacokinetic parameters, and their relationships with
47 accharides into baboons were used to measure pharmacokinetic parameters, and to assess the extent of
48 best combination of potency, properties, and pharmacokinetic parameters, and, while not curative, thi
49 ortional manner; isatuximab and lenalidomide pharmacokinetic parameters appeared independent.
50                                 The nano-OPH pharmacokinetic parameters are improved compared to the
51 te R-13, for which detailed pharmacology and pharmacokinetic parameters are presented.(1)
52 ir physicochemical properties, and attendant pharmacokinetic parameters, are not drug-like.
53                    Primary outcomes were the pharmacokinetic parameters area under the curve (AUC) co
54 ed kinase selectivity profile and acceptable pharmacokinetic parameters, as a promising lead.
55        There were significant differences in pharmacokinetic parameters at 300 mg bid between patient
56  There were no relevant differences in other pharmacokinetic parameters at month 1 or in area under t
57    Conclusion A radiomics score derived from pharmacokinetic parameters at pretreatment dynamic contr
58 re highly variable, but measurement of these pharmacokinetic parameters at the start of maintenance w
59 in microparasite abundance is related to the pharmacokinetic parameter, AUC, recording the area under
60                                 The targeted pharmacokinetic parameters (AUC0-12h and C12h) were achi
61              The insignificant difference in pharmacokinetic parameters between Egyptians and white G
62  poor as a result of moderate variability in pharmacokinetic parameters between patients.
63        Primary outcomes were (1) comparative pharmacokinetic parameters between regimens and (2) recu
64                            The difference in pharmacokinetic parameters between the species is profou
65 though there are differences in some retinal pharmacokinetics parameters between the pigmented and no
66  of any observed CsA concentration, or other pharmacokinetic parameters calculated following a single
67        Specimens were shipped, analyzed, and pharmacokinetic parameters calculated in real-time.
68 mplished by specifically focusing on in vivo pharmacokinetic parameters CL(u), Vdss(u), and MRT.
69 his bispecific IgG also demonstrated in vivo pharmacokinetic parameters comparable to those of the pa
70 gnificant additional effect on dexamethasone pharmacokinetic parameters compared with the standard-do
71 te significant inter-individual variation in pharmacokinetic parameters, concentrations of polyphenol
72                          The enhancement and pharmacokinetic parameters correlated significantly with
73                                              Pharmacokinetic parameters demonstrated that plasma expo
74    In conclusion, PEG-IFN concentrations and pharmacokinetic parameters do not differ between SVRs an
75                                         Drug pharmacokinetics parameters, drug interaction parameters
76 ing, substance, route of application); (iii) pharmacokinetic parameters (e.g. clearance, half-life, a
77                                     The main pharmacokinetic parameters estimated were Cmax, Tmax, t1
78 y significant differences were noted for the pharmacokinetic parameter estimates of ara-G between adu
79 y-mass index (BMI), and height Z scores, and pharmacokinetic parameter estimation of ivacaftor.
80 ice (n = 3/time point) for plasma and tissue pharmacokinetic parameter estimation using LC-MS/MS.
81                                              Pharmacokinetic parameters evaluated included the area u
82                                     The oral pharmacokinetic parameters for (E,Z)-norendoxifen were d
83 cretion were determined on days 1, 2, and 5; pharmacokinetic parameters for blood samples were determ
84     Secondary end points included additional pharmacokinetic parameters for islatravir triphosphate i
85 uated the relationship between genotypes and pharmacokinetic parameters for isoniazid (INH) and rifam
86                                              Pharmacokinetic parameters for PD156707 in dogs are also
87 ed Bayesian estimation to predict individual pharmacokinetic parameters for personalized dosing recom
88 s (t(burst)/tau) were highly correlated with pharmacokinetic parameters for spray-dried microspheres
89                                              Pharmacokinetic parameters for the bolus regimen at the
90                  Secondary outcomes included pharmacokinetic parameters for the once-daily dolutegrav
91 istein, daidzein, and glycitein, and defined pharmacokinetic parameters for their absorption and meta
92                                              Pharmacokinetic parameters for TMZ were calculated by no
93                                        Human pharmacokinetic parameters for tozadenant and preladenan
94                                              Pharmacokinetic parameters for volume of the central com
95 ion to biological ontologies, calculation of pharmacokinetic parameters from concentration-time profi
96 f ceftazidime dosing regimens using the mean pharmacokinetic parameters from this population of patie
97                                          The pharmacokinetic parameter HEF at dynamic gadoxetate-enha
98 sured on enhancement-versus-time curves, and pharmacokinetic parameters (hepatic extraction fraction
99                                 Dolutegravir pharmacokinetic parameters, HIV viral load (VL) data, an
100 ced malignancies, characterize the pertinent pharmacokinetic parameters, identify evidence of viral u
101 after dose (AUC(0-24)) and population plasma pharmacokinetic parameters (ie, absorption rate constant
102         Hepatic metabolic stability is a key pharmacokinetic parameter in drug discovery.
103 ermore, several analogues exhibited improved pharmacokinetic parameters in animal models.
104                                              Pharmacokinetic parameters in children and adolescents w
105    25 mg film-coated tablets did not achieve pharmacokinetic parameters in children weighing 14 kg to
106                                              Pharmacokinetic parameters in dogs were evaluated and an
107               The substantial variability in pharmacokinetic parameters in hemophilia patients A pose
108 blood-brain barrier, and displayed favorable pharmacokinetic parameters in mice, rats, and dogs.
109 ncy against the GRK2 subfamily and favorable pharmacokinetic parameters in mice.
110                                    Pimodivir pharmacokinetic parameters in non-elderly and elderly pa
111 re, fully human DKK1-IgG displayed favorable pharmacokinetic parameters in non-human primates.
112                                    Pimodivir pharmacokinetic parameters in nonelderly and elderly pat
113  (n = 29 ; 11 GG, 10 GT and 8 TT), efavirenz pharmacokinetic parameters in plasma and breast milk dif
114                               GS-1291269 has pharmacokinetic parameters in preclinical species that s
115 , whereas HIV status has little influence on pharmacokinetic parameters in pregnant women.
116 improved hCRH1 receptor binding affinity and pharmacokinetic parameters in the rat.
117 ls (CIs) for comparison of total and unbound pharmacokinetic parameters in the third trimester and po
118 000-fold and can lead to profound effects on pharmacokinetic parameters including clearance, half-lif
119 BCG2 levels associated with higher erlotinib pharmacokinetic parameters, including area under the cur
120  other genes and evaluated associations with pharmacokinetic parameters, including elimination consta
121 based model capable of accurately predicting pharmacokinetic parameters, including half-life, clearan
122 d shutter-speed approach analyses to extract pharmacokinetic parameters, including rate constant for
123 ncidence of chronic rejection and individual pharmacokinetic parameters, including the mean values of
124                                              Pharmacokinetic parameters increased proportionally with
125                                  Whole blood pharmacokinetic parameters indicated a half-life of 18.2
126 alities that may be important for tuning the pharmacokinetic parameters is also described.
127  considerable variability for DCE MR imaging pharmacokinetic parameters (K(trans), k(ep), v(e), iAUGC
128                     For SkBr3, the estimated pharmacokinetic parameters k1 and k3 were consistent wit
129 arallel optimization of potency and in vitro pharmacokinetic parameters led to the identification of
130 f cellular potency, physical properties, and pharmacokinetic parameters led to the identification of
131                 Secondary endpoints included pharmacokinetic parameters, objective response and media
132  the drugs delivered individually, while the pharmacokinetic parameters of 17-AAG were similar in bot
133 yond the pure and simple amelioration of the pharmacokinetic parameters of a drug and might provide a
134 eveloped for the predictive profiling of key pharmacokinetic parameters of a molecule (adsorption, di
135       The primary outcomes were dolutegravir pharmacokinetic parameters of area under the concentrati
136             The coprimary endpoints were the pharmacokinetic parameters of area under the curve (AUC)
137                                          The pharmacokinetic parameters of breast cancer were calcula
138                                          The pharmacokinetic parameters of cantuzumab mertansine, the
139                           Differences in the pharmacokinetic parameters of cholinesterases seem to be
140 etween the most critical physicochemical and pharmacokinetic parameters of CNS drugs as well as their
141                                   Population pharmacokinetic parameters of each drug and between-chil
142              This relationship also held for pharmacokinetic parameters of exposure and 1,5-anhydrogl
143                      This work describes the pharmacokinetic parameters of i.v. administered function
144  tissue distribution, metabolic profile, and pharmacokinetic parameters of i.v.-administered N1,N11-d
145                                Compartmental pharmacokinetic parameters of isoniazid, rifampin, and p
146 postmenstrual age are relevant predictors of pharmacokinetic parameters of morphine and its metabolit
147  were performed periodically posttransplant; pharmacokinetic parameters of Mut-IL-15/Fc were assessed
148                         However, the general pharmacokinetic parameters of peptides, including rapid
149         Allometrically scaled body weight on pharmacokinetic parameters of piperaquine result in lowe
150                                          The pharmacokinetic parameters of RAD showed dose proportion
151  aimed to evaluate the safety, efficacy, and pharmacokinetic parameters of raltegravir (RAL) in human
152        After a single subcutaneous dose, the pharmacokinetic parameters of released semaglutide and b
153                                         Mean pharmacokinetic parameters of rhuMAb HER2 were unaltered
154                                              Pharmacokinetic parameters of TAF and TFV were determine
155 er studies must be conducted to evaluate the pharmacokinetic parameters of the bioactive compounds.
156               All phase 1 trials showed that pharmacokinetic parameters of the biosimilar and respect
157 lasma samples were taken to characterize the pharmacokinetic parameters of this formulation of CAI.
158                                        Using pharmacokinetic parameters of TLZ in humans, we designed
159 itochondrial membrane potential with the key pharmacokinetic parameters of TPP inside the live cells.
160 y-4-cholesten-3-one (C4), and changes in the pharmacokinetic parameters of ursodeoxycholic acid and i
161  is to compare the dosage, concentration and pharmacokinetics parameters of tacrolimus between LDLT a
162 in mice revealed substantial improvements in pharmacokinetic parameters over previously reported 1-ad
163 cluding those that are drug related, such as pharmacokinetic parameters, patient-related differences
164                      Secondary outcomes were pharmacokinetic parameters, pharmacodynamic effects, ove
165 ance of on-target activity, selectivity, and pharmacokinetic parameters, progressed into in vivo stud
166                                 The adequate pharmacokinetic parameters, prominent tumor accumulation
167 opyridones, exemplified by 13, with improved pharmacokinetic parameters relative to the initial lead.
168 pounds were then analyzed for their in vitro pharmacokinetic parameters, revealing favorable absorpti
169 Objectives: We sought to report pyrazinamide pharmacokinetic parameters, risk factors for lower pyraz
170                            For estimation of pharmacokinetic parameters, sample size varied over time
171 posomes injected intravenously into rats has pharmacokinetic parameters similar to control, non-pH-se
172 pha-d-mannoside 9, affinity and the relevant pharmacokinetic parameters (solubility, permeability, re
173            Conclusion: (18)F-MitoPhos showed pharmacokinetic parameters suitable for cardiac imaging.
174    Several of these molecules also exhibited pharmacokinetic parameters suitable for in vivo animal s
175 o obtaining excellent kinase selectivity and pharmacokinetic parameters suitable for oral dosing, whi
176            Serial blood samples to calculate pharmacokinetic parameters taken on Day 1 (first ointmen
177 of ex vivo nude mouse ear skin and extracted pharmacokinetic parameters through convolutional neural
178 abolite correction and calculation of tissue pharmacokinetic parameters to be achieved.
179  clearance rate is one of the most important pharmacokinetic parameters to consider in the design of
180                                 Four primary pharmacokinetic parameters (total clearance, volume of t
181 erived from hyperpolarized (13)C MRI and the pharmacokinetic parameters transfer constant (K (trans))
182 were used to derive rifampicin and meropenem pharmacokinetic parameters using noncompartmental analys
183 n describe doxorubicin pharmacokinetics, and pharmacokinetic parameters vary significantly among the
184                      Five observers measured pharmacokinetic parameters (volume transfer constant [K(
185                                              Pharmacokinetic parameters (volume transfer constant, K(
186                                 No rifamycin pharmacokinetic parameter was consistently and significa
187                                  The primary pharmacokinetic parameter was the trough concentration 2
188 een UGT1A1 genotype (n = 61) and toxicity or pharmacokinetic parameters was observed.
189 able interindividual variability in baclofen pharmacokinetic parameters was observed.
190                      Mean apolipoprotein A-I pharmacokinetic parameters were as follows: half-life 24
191                                              Pharmacokinetic parameters were assessed for single and
192                    Safety, tolerability, and pharmacokinetic parameters were assessed to evaluate the
193                                              Pharmacokinetic parameters were calculated after measure
194                                       Pooled pharmacokinetic parameters were calculated based on a de
195                                              Pharmacokinetic parameters were calculated before and af
196                                              Pharmacokinetic parameters were calculated by noncompart
197                                              Pharmacokinetic parameters were calculated by noncompart
198                                              Pharmacokinetic parameters were calculated from plasma t
199                                              Pharmacokinetic parameters were calculated using a monoe
200 ones were detected by a validated method and pharmacokinetic parameters were calculated using a non-c
201                              Tenofovir (TFV) pharmacokinetic parameters were calculated using a nonco
202                                   Gentamicin pharmacokinetic parameters were calculated using a one-c
203 protein inhibitors, were determined, and the pharmacokinetic parameters were calculated.
204                                              Pharmacokinetic parameters were calculated.
205 ples for pharmacokinetics were collected and pharmacokinetic parameters were calculated.
206                                       CPT-11 pharmacokinetic parameters were comparable to those repo
207                          Dasatinib pediatric pharmacokinetic parameters were comparable with those in
208  datasets were reconstructed, and parametric pharmacokinetic parameters were compared between the 2 r
209                                The estimated pharmacokinetic parameters were compared with expression
210              Whole-tumor-averaged parametric pharmacokinetic parameters were compared with those obta
211 administration during a 24-hr period and the pharmacokinetic parameters were compared.
212                              All of the HPPH pharmacokinetic parameters were consistent with a highly
213                                              Pharmacokinetic parameters were consistent with previous
214                                              Pharmacokinetic parameters were derived from serial whol
215 ect's daptomycin concentration-time data and pharmacokinetic parameters were determined by standard m
216                                              Pharmacokinetic parameters were determined in a noncompa
217                                              Pharmacokinetic parameters were determined using non-com
218                                              Pharmacokinetic parameters were determined using noncomp
219                                     Finally, pharmacokinetic parameters were determined, and a compou
220 s investigated in vitro and in vivo, and the pharmacokinetic parameters were determined.
221 rtery, portal vein, and cardiac output), and pharmacokinetic parameters were directly assessed.
222                                              Pharmacokinetic parameters were estimated by compartment
223                                              Pharmacokinetic parameters were estimated by fitting the
224                                              Pharmacokinetic parameters were estimated by use of two-
225                                              Pharmacokinetic parameters were estimated using a noncom
226 ra-articular and systemic concentrations and pharmacokinetic parameters were estimated using a two-co
227 luorotron Master, an ocular fluorophotometer Pharmacokinetic parameters were estimated using WinNonli
228                                       Plasma pharmacokinetic parameters were evaluated in both normal
229 of absolute neutrophil count (ANC) nadir and pharmacokinetic parameters were evaluated.
230                                              Pharmacokinetic parameters were evaluated.ResultsForty p
231 uration of dialysis, type of filter, and the pharmacokinetic parameters were extracted from each arti
232                                              Pharmacokinetic parameters were further evaluated, revea
233                     Compounds with favorable pharmacokinetic parameters were identified, and two comp
234        In an in vivo study in mice, lycopene pharmacokinetic parameters were improved by lycopene/OEG
235                                              Pharmacokinetic parameters were independent of dose and
236                                              Pharmacokinetic parameters were not prognostic of tumor
237                                              Pharmacokinetic parameters were obtained by noncompartme
238 VMP were determined by the trapezoid method; pharmacokinetic parameters were obtained using noncompar
239 ic adenosine monophosphate pathway, and some pharmacokinetic parameters were preliminarilly evaluated
240                                              Pharmacokinetic parameters were similar at the highest d
241                                              Pharmacokinetic parameters were similar in children and
242          Although PEG-IFN concentrations and pharmacokinetic parameters were similar in sustained vir
243                 Noncompartmental and modeled pharmacokinetic parameters were similar.
244                                              Pharmacokinetic parameters were stable over time.
245 frequencies, percentages, and exact 95% CIs; pharmacokinetic parameters were summarised using descrip
246 ance of CPT enabling simulation of desirable pharmacokinetic parameters with a convenient single-dosi
247  acute lymphoblastic leukemia and correlated pharmacokinetic parameters with disease outcome.
248    Endpoints for the OSP included safety and pharmacokinetic parameters with investigator-evaluated o
249 ively improve the prediction accuracy of the pharmacokinetic parameters with limited observations in
250 oratory values, clinical parameters, and CsA pharmacokinetic parameters with the occurrence of chroni
251 an were obtained during cycle 1 to correlate pharmacokinetic parameters with toxicity.
252 4 demonstrated excellent bioavailability and pharmacokinetic parameters, with good tolerance in roden

 
Page Top